Evidence map›Paper›PMID 35266989›Full record

SynthesisCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

Large-scale Integrated Analysis of Genetics and Metabolomic Data Reveals Potential Links Between Lipids and Colorectal Cancer Risk.

Xiang Shu, Zhishan Chen, Jirong Long, Xingyi Guo, Yaohua Yang, Conghui Qu, Yoon-Ok Ahn, Qiuyin Cai, Graham Casey, Stephen B Gruber and 36 more

Registry-linked trialOpen access · bronzeAbstract readMeta-Analysis
In one paragraph

Synthesis in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors at 20 institutions in 10 countries.

Xiang ShuDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4129-9403
Zhishan ChenDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Jirong LongDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Xingyi GuoDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Yaohua YangDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee.ORCID 0000-0002-3815-7172
Conghui QuPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Yoon-Ok AhnDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of South Korea.
Qiuyin CaiDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee.ORCID 0000-0002-9384-5648
Graham CaseyCenter for Public Health Genomics, University of Virginia, Charlottesville, Virginia.
Stephen B GruberDepartment of Preventive Medicine & USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0001-8656-7822
Jeroen R HuyghePublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0001-6027-9806
Sun Ha JeeDepartment of Epidemiology and Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Republic of South Korea.
Mark A JenkinsCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
Wei-Hua JiaState Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, P.R. China.
Keum Ji JungDepartment of Epidemiology and Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Republic of South Korea.
Yoichiro KamataniLaboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Dong-Hyun KimDepartment of Social and Preventive Medicine, Hallym University College of Medicine, Chucheon, Republic of South Korea.
Jeongseon KimDepartment of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Gyeonggi-do, Republic of South Korea.ORCID 0000-0002-0889-2686
Sun-Seog KweonDepartment of Preventive Medicine, Chonnam National University Medical School, Gwangju, Republic of South Korea.ORCID 0000-0003-2378-8550
Loic Le MarchandUniversity of Hawaii Cancer Center, Honolulu, Hawaii.
Koichi MatsudaLaboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan.ORCID 0000-0001-7292-2686
Keitaro MatsuoDivision of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.ORCID 0000-0003-1761-6314
Polly A NewcombPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Jae Hwan OhCenter for Colorectal Cancer, National Cancer Center Hospital, National Cancer Center, Gyeonggi-do, Republic of South Korea.
Jennifer OseHuntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-2030-9676
Isao OzeDivision of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.ORCID 0000-0002-0762-1147
Rish K PaiDepartment of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, Arizona.ORCID 0000-0002-2692-221X
Zhi-Zhong PanState Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, P.R. China.
Paul D P PharoahDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8494-732X
Mary C PlaydonCancer Control and Population Sciences, Huntsman Cancer Institute and Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah.ORCID 0000-0001-6082-0447
Ze-Fang RenSchool of Public Health, Sun Yat-sen University, Guangzhou, P.R. China.
Robert E SchoenDepartment of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0001-7153-2766
Aesun ShinDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of South Korea.
Min-Ho ShinDepartment of Preventive Medicine, Chonnam National University Medical School, Gwangju, Republic of South Korea.ORCID 0000-0002-2217-5624
Xiao-Ou ShuDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee.ORCID 0000-0002-0711-8314
Xiaohui SunDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Catherine M TangenSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Chizu TanikawaLaboratory of Genome Technology, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Cornelia M UlrichDivision of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.ORCID 0000-0001-7641-059X
Franzel J B van DuijnhovenDivision of Human Nutrition, Wageningen University and Research, Wageningen, the Netherlands.ORCID 0000-0001-8367-2352
Bethany Van GuelpenDepartment of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden.ORCID 0000-0002-9692-101X
Alicja WolkInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-7387-6845
Michael O WoodsMemorial University of Newfoundland, Discipline of Genetics, St. John's, Canada.ORCID 0000-0001-8180-418X
Anna H WuUniversity of Southern California, Preventative Medicine, Los Angeles, California.
Ulrike PetersPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0001-5666-9318
Wei ZhengDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee.ORCID 0000-0003-1226-070X
Vanderbilt University · USAichi Cancer Center · JPFred Hutch Cancer Center · USSun Yat-sen University · CNChonnam National University · KRKorea Health Promotion Institute · KRMemorial Sloan Kettering Cancer Center · USNational Cancer Center · USUniversity of Southern California · USUniversity of Washington · USCancer Center of Hawaii · USHallym University · KRHuman Genome Sciences (United States) · USHuntsman Cancer Institute · USKarolinska Institutet · SEMayo Clinic in Arizona · USMemorial University of Newfoundland · CANew Generation University College · ETRIKEN Center for Integrative Medical Sciences · JPSeoul National University · KR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Data sharing: the Colon Cancer Family Registry CohortU01CA167551 · NCI · UNIVERSITY OF MELBOURNE · PI Daniel David BUCHANAN, Steven Gallinger · 2018 to 2026
$16.8M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
PCPT and SELECT Cohorts: Core Infrastructure Support for Cancer ResearchU01CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2019 to 2023
$5.4M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Adipose tissue-colorectal tumor cross-talk: new targets for breaking the obesity-cancer linkR01CA254108 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HURSTING, STEPHEN D, ULRICH, CORNELIA M · 2021 to 2025
$3.2M
Uncovering Roles of Metabolites in Colorectal Cancer EtiologyR00CA230205 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SHU, XIANG · 2020 to 2022
$888k
Uncovering roles of metabolites in colorectal cancer etiologyK99CA230205 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SHU, XIANG · 2019 to 2020
$194k
NCI NIH HHS K99 CA230205NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA230205NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS R01 CA254108NCI NIH HHS U01 CA182883NCI NIH HHS UG1 CA189974
6 · The paper itself

Abstract

backgroundThe etiology of colorectal cancer is not fully understood.

methodsUsing genetic variants and metabolomics data including 217 metabolites from the Framingham Heart Study (n = 1,357), we built genetic prediction models for circulating metabolites. Models with prediction R2 > 0.01 (Nmetabolite = 58) were applied to predict levels of metabolites in two large consortia with a combined sample size of approximately 46,300 cases and 59,200 controls of European and approximately 21,700 cases and 47,400 controls of East Asian (EA) descent. Genetically predicted levels of metabolites were evaluated for their associations with colorectal cancer risk in logistic regressions within each racial group, after which the results were combined by meta-analysis.

resultsOf the 58 metabolites tested, 24 metabolites were significantly associated with colorectal cancer risk [Benjamini-Hochberg FDR (BH-FDR) < 0.05] in the European population (ORs ranged from 0.91 to 1.06; P values ranged from 0.02 to 6.4 × 10-8). Twenty one of the 24 associations were replicated in the EA population (ORs ranged from 0.26 to 1.69, BH-FDR < 0.05). In addition, the genetically predicted levels of C16:0 cholesteryl ester was significantly associated with colorectal cancer risk in the EA population only (OREA: 1.94, 95% CI, 1.60-2.36, P = 2.6 × 10-11; OREUR: 1.01, 95% CI, 0.99-1.04, P = 0.3). Nineteen of the 25 metabolites were glycerophospholipids and triacylglycerols (TAG). Eighteen associations exhibited significant heterogeneity between the two racial groups (PEUR-EA-Het < 0.005), which were more strongly associated in the EA population. This integrative study suggested a potential role of lipids, especially certain glycerophospholipids and TAGs, in the etiology of colorectal cancer.

conclusionsThis study identified potential novel risk biomarkers for colorectal cancer by integrating genetics and circulating metabolomics data. IMPACT: The identified metabolites could be developed into new tools for risk assessment of colorectal cancer in both European and EA populations.

Indexed as

Colorectal NeoplasmsAsian PeopleCase-Control StudiesGlycerophospholipidsHumansLipidsMetabolomicsGlycerophospholipidsLipids

Identifiers

PMID35266989
PMCPMC9354799
OpenAlexW4220887859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.